Immunogenicity of an Escherichia coli multivalent pilus vaccine in chickens

Immunogenicity of an oil-emulsified Escherichia coli multivalent pilus vaccine was evaluated in 4-week-old chickens. The vaccine contained 180 micrograms of pilus protein from each of serotypes O1 and O78 and 170 micrograms of pilus protein from serotype O2. Chickens were vaccinated twice subcutaneously at 4 and 6 weeks old and challenged via the posterior thoracic air sac with E. coli serotype O1, O2, or O78 2 weeks after the last vaccination. Unvaccinated challenged chickens suffered 8% to 26% mortality; no vaccinated chickens died. Vaccinated chickens had very mild gross lesions in the air sacs, livers, and pericardial sacs and eliminated E. coli more efficiently than the unvaccinated challenged chickens. The results showed that a multivalent pilus vaccine protects chickens against active respiratory infection.     

CpG寡核苷酸对IBDV VP2基因真核表达质粒免疫增效作用

以传染性法氏囊病病毒(IBDV)VP2蛋白基因表达质粒DNA为免疫原，以CpG的寡核苷酸(CpG-0DN)为免疫佐剂，肌肉注射于14日龄SPF鸡，1周后加强免疫1次，2次免疫后15d和21d分别测定血清ELISA抗体效价，并于免疫后21d用IBDV99儿强毒株攻毒和进行病理学观察。结果显示，(1)VP2基因重组质粒DNA与CpG共同免疫组的ELISA抗体水平明显高于VP2重组质粒免疫组；(2)IBD弱毒苗与VP2重组质粒免疫组抗体水平明显高于VP2重组质粒免疫组，且比VP2基因重组质粒DNA与CpG共同免疫组略高；(3)VP2基因重组质粒DNA与CpG共同免疫组及IBD弱毒苗与VP2重组质粒免疫组可明显降低IBDV强毒攻击后引起的急性发病率和死亡率。由此表明，CpG寡核苷酸对IBDV VP2蛋白基因真核表达质粒免疫具有明显增强作用，有很大的应用前景。     

Effect of the Immunity Efficacy of IBD Immune Complex Vaccine on ND La Sota Vaccine

1-day-old SPF chickens and commercial Jingfen chickens were vaccinated with IBD immune complex(IC) vaccine, NDV La Sota vaccine were inoculated simultaneously every one week and every two weeks.NDV La Sota immunization alone was as the control group.At the 2nd, 3rd, 4th and 5th week post inoculation, blood samples were taken and the ND HI antibody were tested.Experimental chickens were challenged with high virulent NDV at the 5th week post inoculation, the protective rate of each group was calculated.The results showed the ND HI antibody were not significant different in the combined immunization of IBD IC vaccine priming and NDV La Sota vaccine boost and NDV La Sota vaccine alone immunization (P>0.05).The results indicated that IBD IC vaccine has no immunosuppression on NDV La Sota vaccine in SPF chickens and commercial Jingfen chickens.     

Newcastle disease virus strain I2--a prospective thermostable vaccine for use in developing countries.

Forty-five avirulent Australian strains of Newcastle disease virus had been examined for antigenicity in chickens and 18 of these were tested for thermostability. Strain I2, chosen for a combination of antigenicity and thermostability, was artificially selected for enhanced thermostability. Master seed material was then prepared in minimal disease eggs, and vaccine by a further two passages in conventional eggs. Strain I2 virus at seed and vaccine level induced adequate levels of antibody in chickens vaccinated by eye drop and usually in their contacts. The serological response to oral vaccination was less certain. Antibody titres indicative of substantial protection against virulent challenge were maintained in a simulated village flock for 38 weeks by vaccination of the foundation flock on two occasions, with subsequent vaccination confined to clutches of chicks as they were produced. Strain I2 virus survived for at least 12 weeks when stored at 22 degrees C in 1% gelatin. Strain I2 is suitable for local production of thermostable vaccine in regional laboratories in developing countries.     

Vaccination of chickens using raw rice coated with novel trehalose nano-organogels containing Newcastle disease (strain I-2) vaccine

The formulation and evaluation of trehalose nano-organogels for storage and oral delivery of Newcastle disease (ND) strain I-2 vaccine to chickens were carried out in this study. Trehalose sugar was blended with vegetable oil to form nano-organogels where trehalose also acted as a stabilizer against thermal inactivation of I-2 ND virus. Results from infectivity titration assay indicated that the titre of 10^7.5 EID₅₀/0.1 mL was maintained after 12 weeks of storage of nano-organogel I-2 vaccine at ambient room temperature. Serology results showed that 33% chickens which were vaccinated with nano-organogel I-2 vaccine after 14 days had HI antibody titres of ≥ 3.0 log₂ with GMT of 2.3. Moreover, results showed 100% of chickens vaccinated with nano-organogel I-2 vaccine had the mean antibody titres of 3.4 and 3.7 log₂ at 21 and 28 days after vaccination, respectively. All vaccinated chickens (100%) survived the challenge of virulent ND virus whereas all unvaccinated chickens succumbed to challenge and died of signs consistent with ND. The findings from this study showed that the nano-organogel I-2 vaccine was stable at room temperature, safe and produced protective antibody response in vaccinated chickens. Moreover the nano-organogel I-2 vaccine was used for oral administration and hence is suitable for mass vaccination. However, optimization of the formulation of trehalose nano-organogel vaccine is required in order to achieve its application potentials.     

鸡传染性贫血免疫对肝微粒体抗氧化酶活性的影响

目的是观察鸡传染性贫血多次免疫对肝微粒体中抗氧化酶活性的影响.对20只SPF鸡随机分为2组,每组10只,免疫组鸡用鸡传染性贫血弱毒苗免疫4次,每次间隔2周,对照组鸡注射同剂量的生理盐水.最后一次免疫后10d取肝脏制备微粒体,利用测试盒测定肝微粒体中的GSH-Px活性、SOD活性、CAT活性和MDA含量.结果与对照组相比,免疫组肝微粒体中GSH Px活性、SOD活性和CAT活性都显著提高(P＜0.05),MDA含量显著减低(P＜0.05).结论为鸡传染性贫血多次免疫可提高鸡体抗氧化能力.     

Protective antibody response produced by the chickens vaccinated with green coloured thermostable Newcastle disease virus

The efficacy of green-coloured (GC) I-2 Newcastle disease vaccine was determined in the present study. I-2 vaccine was mixed with a green coloured dye and stored at 4°C for 6 months while assayed for the virus infectivity at a monthly interval. Chickens were vaccinated with the GC vaccine by eye drop. Serum samples were collected from all birds before and after vaccination at weekly interval for 4 weeks and tested for haemagglutination-inhibition (HI) antibody against Newcastle disease virus (NDV). These chickens were challenged with NDV virulent strain four weeks after vaccination. The results showed that there was no difference between the infectivity titres of GC and uncoloured vaccines. However, chickens vaccinated with GC vaccine produced higher HI antibody titres than chickens vaccinated with uncoloured vaccine. Results from the challenge trial showed that all vaccinated chickens survived whereas all unvaccinated chickens died. The findings from this study have shown that the GC vaccine is safe and produced protective antibodies against NDV in vaccinated chickens. Wambura, P. N., 2008. Protective antibody response produced by the chickens vaccinated with green coloured thermostable Newcastle disease virus. Tropical Animal Health and Production.     

新城疫La Sota疫苗对山东分离株的免疫保护试验

用标准疫苗株La Sota活疫苗在隔离器中接种SPF鸡,进行免疫保护试验.免疫后,每7 d采血监测NDV抗体,免疫后2周,利用经过鉴定的新城疫病毒(NDV)潍坊毒SGM01、昌乐毒SCL03、东营毒HY、日照毒SRZ03、莘县毒SSX03和标准强度F48E9分别进行攻毒试验,同时设SPF鸡对照.每天观察,及时剖检发病鸡,检查鸡群病变,确定疫苗的保护性.结果表明,La Sota疫苗能对除SGM01和HY以外的病毒攻击的SPF鸡提供较好的保护.     

Evaluation of immune effects of fowlpox vaccine strains and field isolates

The immune effects of fowlpox virus (FPV) field isolates and vaccine strains were evaluated in chickens infected at the age of 1 day and 6 weeks. The field isolates and the obsolete vaccine strain (FPV S) contained integrated reticuloendotheliosis virus (REV) provirus, while the current vaccine strain (FPVST) carries only REV LTR sequences. An indirect antibody ELISA was used to measure the FPV-specific antibody response. The non-specific humoral response was evaluated by injection of two T-cell-dependent antigens, sheep red blood cells (SRBC) and bovine serum albumin (BSA). There was no significant difference in the antibody response to FPV between chickens infected with FPV various isolates and strains at either age. In contrast, antibody responses to both SRBC and BSA were significantly lower in 1-day-old chickens inoculated with field isolates and FPV S at 2-3 weeks post-inoculation. Furthermore, cell-mediated immune (CMI) responses measured by in vitro lymphocyte proliferation assay and in vivo using a PHA-P skin test were significantly depressed in chickens inoculated with field isolates and FPV S at the same periods. In addition, thymus and bursal weights were lower in infected chickens. These immunosuppressive effects were not observed in chickens inoculated with the current vaccine strain, FPVST, at any time. The results of this study suggest that virulent field isolates and FPV S have immunosuppressive effects when inoculated into young chickens, which appeared in the first 3 weeks post infection. REV integrated in the FPV field isolates and FPV S may have played a central role in the development of immunosuppression.     

新城疫分离株免疫保护试验

对经过鉴定的新城疫病毒穴NDV雪分离株,按国家兽医生物制品质量标准制备油乳剂灭活疫苗,在隔离器中接种SPF鸡,设标准LaSota疫苗株作对照,进行免疫保护实验。免疫后,每7d采血监测NDV抗体。免疫后3周,利用ND强毒分离毒和F48E9分别进行交叉攻毒实验,同时设SPF鸡对照。每天观察,及时剖检发病鸡,检察鸡群病变,以确定疫苗的保护性,以便对常规生产中的免疫失败进行原因分析。     

禽脑脊髓炎的调查及病毒分离

对陕西省宝鸡、渭南等地的24个鸡群进行了禽脑脊髓炎（AE）的调查,所调查鸡群都有产蛋下降史或产蛋正在下降,下降幅度平均为17.2%。用琼扩试验（AGP）检测所采集的256份血清,AE阳性率平均高达85.6%。有10个鸡群阳性率达100%。跟踪调查2个种鸡群,发现孵出的雏鸡从3日龄开始发病,而且有AE的症状,采发病雏鸡的脑组织,接种6龄鸡胚分离病毒,连传3代,琼扩检测分离毒,呈AE抗原阳性,人工感染1日龄雏鸡复制出与原发病鸡群相同的疾例,表明分离毒是AE病毒。     

Influence of infectious bronchitis strains and vaccines on the incidence of Mycoplasma synoviae airsacculitis

A model system was used to study infectious bronchitis virus (IBV) and Mycoplasma synoviae (MS) interaction. The system involved exposure of chickens to IBV, followed by exposure to MS 2-5 days later. The chickens were subjected to a cold environment (10 +/- 2 C) for 3 weeks starting one day before MS exposure. Under these conditions, differences in the capacity of various strains of IBV to exacerbate MS airsacculitis was demonstrated. Exposure to IBV field isolates generally resulted in more air-sac lesions than did higher-egg-passaged laboratory strains and vaccine strains. Use of lower-egg-passaged vaccines resulted in a higher incidence of airsacculitis than did higher-egg-passaged vaccines. When chickens were IBV-vaccinated before being used in the model system, the incidence of airsacculitis was lowered, even though the chickens became infected by the challenge virus. Vaccination of MS-free chickens with IBV had no effect on airsacculitis incidence when MS exposure occurred after the vaccine reaction was past.     

IBDV地方野毒株不同毒源二价灭活油乳苗免疫效果的比较研究

对利用IBDV地方野毒株所制备的囊毒和胚毒二价灭活油乳苗免疫效果进行了比较研究。结果表明,所制备的囊毒灭活苗免疫效果显著优于胚毒灭活苗和活疫苗,在接种后各个时期所产生的抗体效价均显著高于其它两种疫苗(P<0.01),最高AGP效价可达4.8log2;胚苗的免疫效果虽然差于囊苗,但明显优于活疫苗,当活苗免疫组鸡血清中已无可测性抗体时,胚苗组仍具有1.0log2的AGP效价。在攻毒试验中,囊苗组鸡对IBDV标准毒、两株野毒株的攻击均100%地获得了保护;胚苗组也均可获得80%的保护,这两种由地方毒株所制备的疫苗均未呈现出对不同毒株抵抗性的不同,而活苗组对不同毒株的攻击则分别只有53.3%、40%和46.7%的保护率,呈现出一定的差异性。     

Immunogenicity of a DNA vaccine of Avian Reovirus orally delivered by attenuated Salmonella typhimurium

This study aimed to assess the ability of a Salmonella typhimurium-mediated Avain Reovirus DNA vaccine in eliciting antibody production. Six-day-old SPF chickens were orally immunized with SL7207 (pVAX-σC) twice at 2-week interval, detectable antibody was generated 2 weeks after immunization and was significantly higher than the control groups (P<0.01) and ten chickens (66.7%) were considered safe in the subsequent challenge. These results show that SL7207 (pVAX-σC) can induce protective antibody in chickens and the newly-constructed vaccine is also effective in protection chickens against ARV infection.     

Vaccination with an autogenous bacterin fails to prevent colonization by Brachyspira intermedia in experimentally infected laying chickens

Avian intestinal spirochaetosis (AIS) is a disease complex affecting adult laying and breeding chickens associated with infection by anaerobic intestinal spirochaetes of the genus Brachyspira. Options for control of AIS are limited, as few effective antimicrobial agents are registered for use in laying chickens. One of the two most commonly encountered pathogenic species in AIS is B. intermedia, and the aim of the current study was to determine whether a B. intermedia bacterin vaccine would help control AIS caused by this species. An autogenous bacterin was prepared from B. intermedia strain HB60 and given twice intramuscularly at a 3-week interval to 12 laying chickens housed in individual cages. Twelve non-vaccinated control chickens were placed in adjacent cages in the same room. Two weeks after the second vaccination all the chickens were experimentally challenged with B. intermedia HB60 by crop tube. Subsequently faeces were cultured for spirochaetes every 2-3 days, faecal water content and chicken weight were measured weekly, and egg numbers and weights were recorded daily. Serum was taken prior to both vaccinations, at the time of challenge and at euthanasia. The chickens were killed 6 weeks post-challenge. The vaccinated chickens showed seroconversion to the vaccine, but antibody levels declined significantly post-infection. In comparison, the non-vaccinated chickens showed seroconversion post-infection. The reason for the reduction in the antibody levels in the vaccinated chickens after infection was not explained. At some point all the chickens excreted spirochaetes in their faeces, and the duration of excretion was not different between vaccinated and non-vaccinated chickens. There were no differences in faecal water content, chicken weights, egg production, or gross and microscopic caecal lesions between vaccinated and non-vaccinated chickens. In conclusion, an autogenous bacterin vaccine did not prevent infection with B. intermedia in laying chickens.     

Effects of vaccine dose, virus challenge dose and interval from vaccination to challenge on protection of broiler chickens against Marek's disease virus challenge

OBJECTIVES: To examine the effects of varying the doses of turkey herpesvirus (HVT) vaccine and Marek's disease virus (MDV) challenge at two intervals after vaccination on the protection of chickens against challenge with MDV. DESIGN AND PROCEDURE: Experiment 1, a dose response study, consisted of 11 doses of HVT vaccine administered at hatch followed by challenge with 100 plaque forming units (pfu) of MDV 5 days post vaccination. Experiment 2, a 2 x 6 x 2 factorial design, included two HVT vaccine types, six different doses of HVT vaccine and 50 pfu and 200 pfu of MDV challenge 2 days post vaccination. All chickens were reared up to day 56 post challenge when all survivors were killed humanely. Dead and killed chickens were examined for gross MD tumours. RESULTS: Experiment 1 showed a significant positive linear relationship between dose of HVT vaccine and protective index in chickens challenged 5 days post vaccination. However the range of protective index observed was limited. In Experiment 2 neither HVT vaccine provided significant protection at any dose. There was no significant effect of vaccine type or MDV challenge dose on overall protection against challenge. Chickens challenged with 200 pfu of MDV had significantly higher mortality and MD incidence than those with 50 pfu. CONCLUSIONS: HVT vaccine dose had a significant impact on protective index, but vaccination to challenge interval appeared to have greater impact on the protective efficacy of vaccination. A fourfold increase in challenge dose increased mortality rate and incidence of MD.     

A single dose of inactivated oil-emulsion bivalent H5N8/H5N1 vaccine protects chickens against the lethal challenge of both highly pathogenic avian influenza viruses

In this study, two highly pathogenic avian influenza (HPAI) H5N8 viruses were isolated from chicken and geese in 2018 and 2019 (Chicken/ME-2018 and Geese/Egypt/MG4/2019). The hemagglutinin and neuraminidase gene analyses revealed their close relatedness to the clade-2.3.4.4b H5N8 viruses isolated from Egypt and Eurasian countries. A monovalent inactivated oil-emulsion vaccine containing a reassortant virus with HA gene of the Chicken/ME-2018/H5N8 strain and a bivalent vaccine containing same reassortant virus plus a previously generated reassortant H5N1 strain (CK/Eg/RG-173CAL/17). The safety of both vaccines was evaluated in specific-pathogen-free (SPF) chickens. To evaluate the efficacy of the prepared vaccines, 2-week-old SPF chickens were vaccinated with 0.5 mL of a vaccine formula containing 10⁸/EID₅₀ /dose from each strain via the subcutaneous route. Vaccinated birds were challenged with either wild-type HPAI-H5N8 or H5N1 viruses separately at 3 weeks post-vaccine. Results revealed that both vaccines induced protective hemagglutination-inhibiting (HI) antibody titers as early as 2 weeks PV (≥5.0 log₂). Vaccinated birds were protected clinically against both subtypes (100 % protection). HPAI-H5N1 virus shedding was significantly reduced in birds that were vaccinated with the bivalent vaccine; meanwhile, HPAI-H5N8 virus shedding was completely neutralized in both tracheal and cloacal swabs after 3 days post-infection in birds that had been vaccinated with either vaccine. In conclusion, the developed bivalent vaccine proved to be efficient in protecting chickens clinically and reduced virus shedding via the respiratory and digestive tracts. The applicability of the multivalent avian influenza vaccines further supported their value to facilitate vaccination programs in endemic countries.     

油乳剂灭活疫苗不同接种途径的效力比较试验

采用北京市农林科学院畜牧兽医研究所免疫预防研究室制备的鸡新城疫、传染性支气管炎、减蛋综合征、传染性脑脊髓炎四联灭活疫苗,分别经颈背侧皮下、胸部肌肉及腿部肌肉共3个部位免疫SPF鸡,免疫后采血,测定ND、IB、EDS HI抗体,并用AEV VR株强毒攻击,攻毒后观察疫苗保护效果,比较不同接种部位对油乳剂灭活疫苗效力的影响。结果证明,经颈背侧皮下、胸部肌肉及腿部肌肉3个部位免疫均可产生同样好的免疫效力。     

Safety and efficacy of the cell-associated vaccine prepared by an attenuated infectious laryngotracheitis virus.

The safety and efficacy of the cell-associated (C-A) vaccine prepared by chicken embryo fibroblast (CEF) cells infected with the tissue-culture-modified strain of infectious laryngotracheitis (ILT) virus were studied in chickens. Over seventy percent of chickens inoculated with the C-A vaccine by the subcutaneous (S.C.) or intramuscular (I.M.) route at 1 day of age was protected against challenge with a virulent strain of ILT virus without any clinical signs. Chickens vaccinated with the C-A vaccine at 1 day of age acquired immunity within 6 days after vaccination, and the protection rate maintained more than 60% until 10 weeks post-vaccination. The C-A vaccine was invariably effective for chickens at various age. There was no evidence that the development of immunity was hindered by further vaccination with Newcastle disease and infectious bronchitis combined live vaccine. In addition, the C-A vaccine was safe when chickens were inoculated with 10 doses. In the field trials of the C-A vaccine, no adverse reaction was observed, and over 65% of vaccinated chickens was protected against the challenge of the virulent ILT virus at 8 weeks after vaccination.     

Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease

White leghorn chickens on five farms were given a bivalent Marek's disease (MD) vaccine consisting of turkey herpesvirus (HVT) and SB-1 (a nononcogenic MD virus); other chickens received only HVT. The farms had histories of "vaccination failures," presumably owing to an exceptionally virulent challenge MD virus. The bivalent vaccine uniformly protected chickens better than HVT alone between 12 and 16-20 weeks of age, when serious MD losses occurred. During that period, total mortality in groups given both viruses ranged from 0.39 to 1.26% (mean 0.86%), whereas that in HVT-vaccinated groups not exposed to SB-1 varied from 1.92 to 7.44% (mean 3.43%). Chickens in pens or rows with close contact to those given bivalent vaccine also had low MD mortality rates (0.46-1.06%, mean 0.77%), probably from the spread of SB-1.